CA3234818A1 - R-ketamine salts and methods of use thereof - Google Patents

R-ketamine salts and methods of use thereof Download PDF

Info

Publication number
CA3234818A1
CA3234818A1 CA3234818A CA3234818A CA3234818A1 CA 3234818 A1 CA3234818 A1 CA 3234818A1 CA 3234818 A CA3234818 A CA 3234818A CA 3234818 A CA3234818 A CA 3234818A CA 3234818 A1 CA3234818 A1 CA 3234818A1
Authority
CA
Canada
Prior art keywords
ketamine
salt
pxrd
peaks
crystalline polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3234818A
Other languages
English (en)
French (fr)
Inventor
Mouhannad Jumaa
Terence Alfred Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perception Neuroscience Inc
Original Assignee
Perception Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perception Neuroscience Inc filed Critical Perception Neuroscience Inc
Publication of CA3234818A1 publication Critical patent/CA3234818A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3234818A 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof Pending CA3234818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254878P 2021-10-12 2021-10-12
US63/254,878 2021-10-12
PCT/US2022/046412 WO2023064363A1 (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3234818A1 true CA3234818A1 (en) 2023-04-20

Family

ID=84331621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3234818A Pending CA3234818A1 (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof

Country Status (8)

Country Link
US (1) US20240336556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416126A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539623A (cg-RX-API-DMAC10.html)
CN (1) CN118647595A (cg-RX-API-DMAC10.html)
CA (1) CA3234818A1 (cg-RX-API-DMAC10.html)
IL (1) IL312041A (cg-RX-API-DMAC10.html)
MX (1) MX2024004478A (cg-RX-API-DMAC10.html)
WO (1) WO2023064363A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444041A2 (en) 2001-09-21 2004-08-11 Solvias AG Sealing system with flow channels
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019065900A1 (ja) 2017-09-27 2019-04-04 国立大学法人千葉大学 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
US20220110889A1 (en) 2018-12-27 2022-04-14 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
EP3968979B1 (en) * 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation

Also Published As

Publication number Publication date
MX2024004478A (es) 2024-07-01
US20240336556A1 (en) 2024-10-10
CN118647595A (zh) 2024-09-13
WO2023064363A9 (en) 2024-02-15
WO2023064363A1 (en) 2023-04-20
EP4416126A1 (en) 2024-08-21
IL312041A (en) 2024-06-01
JP2024539623A (ja) 2024-10-29

Similar Documents

Publication Publication Date Title
JP2021113225A (ja) 2−ヒドロキシ−6−((2−(1−イソプロピル−1h−ピラゾール−5−イル)ピリジン−3−イル)メトキシ)ベンズアルデヒドの遊離塩基の結晶多形
JP7199739B2 (ja) Gabaaの正のアロステリックモジュレーターの塩及び結晶形態
TW202409008A (zh) 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體
ES2429348T3 (es) Cocristales farmacéuticamente aceptables de N-[2-(7-metoxi-1-naftil)etil]acetamida y procedimientos para su preparación
JP2025511847A (ja) ラニフィブラノールの結晶形態
CN101573350A (zh) 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼
JP2010527371A (ja) N−(4−フルオロベンジル)−n−(1−メチルピペリジン−4−イル)−n’−(4−(2−メチルプロピルオキシ)フェニルメチル)カルバミドならびにその酒石酸塩および各種の結晶形の合成
JP7842805B2 (ja) フマギロール誘導体およびその多形体
EP3360858A1 (en) Process for producing an aminopyrrolidine derivative
EP3743405B1 (en) Crystalline siponimod fumaric acid and polymorphs thereof
HU231013B1 (hu) Dasatinib sók
JP2026048695A (ja) Lsd塩結晶形態
EA005529B1 (ru) Цитрат 5,8,14-триазатетрацикло-(10.3.1.0.0)-гексадека-2(11),3,5,7,9-пентаена
AU2011334928A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
US20240336556A1 (en) R-ketamine salts and methods of use thereof
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
JP2023116756A (ja) 置換キノキサリン型架橋ピペリジン化合物の多形形態
US11208382B2 (en) Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
JP2025533955A (ja) (2s,5r)-5-(2-クロロフェニル)-1-(2’-メトキシ-[1,1’-ビフェニル]-4-カルボニル)ピロリジン-2-カルボン酸の多形およびその調製プロセス
JP2025524904A (ja) ダプロデュスタットおよびその共結晶を調整するための方法
EP2729460B1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
CN115448895B (zh) 一种沃替西汀前药的晶型、其制备方法和应用
JP7779846B2 (ja) (1r,3s)-3-(5-シアノ-4-フェニル-1,3-チアゾール-2-イルカルバモイル)シクロペンタンカルボン酸の共結晶
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251027